Palvella Therapeutics, Inc.

As of June 30, 2026, Palvella Therapeutics, Inc. carries a market capitalization of 1.93B, placing it among publicly traded companies globally. Its enterprise value stands at 1.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Palvella Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Palvella Therapeutics, Inc. has 14.40M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Palvella Therapeutics, Inc. maintains a current ratio of 21.18, meaning it holds 21.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.25, indicating conservative leverage, while an interest coverage ratio of -7.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Palvella Therapeutics, Inc. posted a negative return on equity (ROE) of -46.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.70, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 25.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Palvella Therapeutics, Inc.'s stock has gained approximately 76.38% over the past 52 weeks. The 50-day moving average sits at 124.96, while the 200-day moving average is 109.33.

Over the twelve months ended June 30, 2026, Palvella Therapeutics, Inc. generated - - in revenue and converted that into -54.00M in net income, yielding earnings per share of -4.30. EBITDA reached -50.54M, while operating income came in at -50.54M.

As of June 30, 2026, Palvella Therapeutics, Inc. holds 219.34M in cash and equivalents against 468,285.50 in total debt, resulting in a net debt position of -164.38M. Total book value stands at 189.82M, with working capital of 211.02M providing operational flexibility.

Palvella Therapeutics, Inc. produced -31.96M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.81, meaning Palvella Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Palvella Therapeutics, Inc.'s most recent stock split took place on April 23, 2024 with a 80:1 split ratio.

As of June 30, 2026, Palvella Therapeutics, Inc. has an Altman Z-Score of 35.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.